Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Cos. Find Deals, Dollars at J.P. Morgan

BIOTECH: HL Buys, Sells; New Partnership Unveiled for Illumina

Debut Looks to Move Drug Manufacturing Forward

San Diego-Based Co. Closes $2.6 Million Seed Round

Neurocrine Deal Potentially Worth $412 Million

Company Would Pay Idorsia If It Licenses Drug

San Diego Companies Find Deals and Dollars at Health Conference

Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.

Tease photo

Neurocrine Gains Option to License Epilepsy Drug; Deal Worth up to $412M

San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.

DNA Sequencing Company Element Biosciences Raises $80.3M Round

Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.

Tandem Diabetes Software Gets FDA OK

Closed-Loop System Controls Low and High Blood Sugar.

Tease photo

Epirium to Take on Muscle Diseases, Aging

BIOTECH: Company focused on mitochondria health, raises $85M round

Boosting ambitious plans, Epirium recently secured an $85 million Series A round, amid greater investment in muscle therapies.

Foundation Readies To Take On Ultra-Rare Diseases

Former Ionis CEO To Take Helm At Nonprofit.

Medical Device Cos. Applaud Tax Repeal

HEALTH: Excise Tax Was an ACA Financing Mechanism

A recently signed federal spending bill repealed a 2.3% excise tax on medical device makers that was scheduled to resume this month, a boon to San Diego’s medtech industry.

Tease photo

More stories >>